Patterns of Glaucoma in Glaucoma Subspecialty Clinics in Egypt and India in the Year 2018

April 2, 2018 updated by: Rana H. Amin, Kasr El Aini Hospital
In this study, we are aiming to identify the patterns of glaucoma observed and treated at Glaucoma Subspecialty Clinics of Kasr Al-Aini Hospital, Cairo University in Cairo, Egypt and corresponding clinics in Sadguru Netra Chikitsalaya Post Graduate Institute of Ophthalmology in Mumbai, Maharashtra, India during the year 2018. We are hoping that this study would provide an update on current statistics available on Indian population as well as provide novel numbers on the prevalence of glaucoma and its patterns in one of the largest tertiary care hospitals in Egypt. These results will then be compared to patterns observed in other epidemiological studies done in other countries.

Study Overview

Study Type

Observational

Enrollment (Anticipated)

2500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Cairo, Egypt, 11562
        • Recruiting
        • Kasr Al-Aini Hospital, Cairo University
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Rasha Mounir, M.D.
        • Sub-Investigator:
          • Yasmine M. El-Sayed, M.D.
        • Sub-Investigator:
          • Reham S. Allam, M.D.
        • Sub-Investigator:
          • Mohammed Sabry, M.D.
      • Mumbai, India, 400020
        • Recruiting
        • two centres: Kasr Al-Aini Hospital in Cairo and Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology
        • Contact:
          • Rakesh Shakya, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients referred to and following up in the glaucoma sub-specialty clinics in the year 2018 in two centres: Kasr Al-Aini Hospital in Cairo and Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology in India

Description

Inclusion Criteria:

  • All patients referred to glaucoma sub-specialty clinics in the year 2018 in two centres: Kasr Al-Aini Hospital in Cairo and Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology in India

Exclusion Criteria:

  • Patients younger than 18 years old.
  • Patients with incomplete examination data

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group A
Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
recording of patient data and its input into an excel sheet from which statistics will be derived
Group B
Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
recording of patient data and its input into an excel sheet from which statistics will be derived

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patterns of Glaucoma
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
Determining patterns of glaucoma seen in one year in glaucoma sub-specialty clinics in two countries: Egypt and India
12 months starting january 1st, 2018 til December 31st, 2018
Demographic data
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
Determining demographic data with respect to age and gender in different types of glaucoma in each country
12 months starting january 1st, 2018 til December 31st, 2018

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anti-glaucoma treatment
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
Determining details of anti-glaucoma treatment used in each country
12 months starting january 1st, 2018 til December 31st, 2018
Positive family history
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
Determining percentage of patients with positive family history in each country
12 months starting january 1st, 2018 til December 31st, 2018
Management decisions
Time Frame: 12 months starting january 1st, 2018 til December 31st, 2018
Determining different management decisions taken by doctors in each country
12 months starting january 1st, 2018 til December 31st, 2018

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Anticipated)

December 31, 2018

Study Completion (Anticipated)

December 31, 2018

Study Registration Dates

First Submitted

April 2, 2018

First Submitted That Met QC Criteria

April 2, 2018

First Posted (Actual)

April 9, 2018

Study Record Updates

Last Update Posted (Actual)

April 9, 2018

Last Update Submitted That Met QC Criteria

April 2, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 12CM

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

statistics obtained from data collected

IPD Sharing Time Frame

january 1st 2018 til december 31st 2018

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on collection of data from patient files

3
Subscribe